6550 Polar Vertex Pharma-KY: Announcement Regarding Change of Director at Subsidiary Lin-Yang Biotechnology
Polar Vertex Pharma-KY announced the change of a director at its subsidiary, Lin-Yang Biotechnology (Cayman Islands entity). Following a reappointment by the parent company, Mr. Chen Hung-wen has resigned, and Mr. Hou Yu-hsiang, the current HR Director, has been appointed as the new director.
📋 Article Processing Timeline
- 📰 Published: May 26, 2026 at 06:31
- 🔍 Collected: May 26, 2026 at 06:31 (0 min after Published)
- 🤖 AI Analyzed: May 26, 2026 at 07:36 (1h 4m after Collected)
Announcement Date: 2026/05/26
Announcement Time: 19:09:08
Company Code: 6550
Company Name: Polar Vertex Pharma-KY
Subject: Announcement of change of director at subsidiary Lin-Yang Biotechnology Co., Ltd.
Applicable Clause: Clause 6
Event Date: 2026/05/25
Explanation:
1. Date of change: 2026/05/25
2. Type of personnel appointed or changed: Individual director
3. Title and name of the predecessor: Chen Hung-wen, Director of Lin-Yang Biotechnology Co., Ltd.
4. Resume of the predecessor: Director of Lin-Yang Biotechnology Co., Ltd.
5. Title and name of the successor: Hou Yu-hsiang, Director of Lin-Yang Biotechnology Co., Ltd.
6. Resume of the successor: HR Director at Lin-Yang Biotechnology
7. Circumstances of change: Resignation
8. Reason for change: Reassignment by the parent company
9. Shareholding at the time of appointment: Not applicable
10. Original term: Not applicable
11. Effective date of appointment: Not applicable
12. Ratio of change in directors during the same term: Not applicable
13. Ratio of change in independent directors during the same term: Not applicable
14. Ratio of change in supervisors during the same term: Not applicable
15. Whether more than one-third of directors have changed: No
16. Other notes: None
Announcement Time: 19:09:08
Company Code: 6550
Company Name: Polar Vertex Pharma-KY
Subject: Announcement of change of director at subsidiary Lin-Yang Biotechnology Co., Ltd.
Applicable Clause: Clause 6
Event Date: 2026/05/25
Explanation:
1. Date of change: 2026/05/25
2. Type of personnel appointed or changed: Individual director
3. Title and name of the predecessor: Chen Hung-wen, Director of Lin-Yang Biotechnology Co., Ltd.
4. Resume of the predecessor: Director of Lin-Yang Biotechnology Co., Ltd.
5. Title and name of the successor: Hou Yu-hsiang, Director of Lin-Yang Biotechnology Co., Ltd.
6. Resume of the successor: HR Director at Lin-Yang Biotechnology
7. Circumstances of change: Resignation
8. Reason for change: Reassignment by the parent company
9. Shareholding at the time of appointment: Not applicable
10. Original term: Not applicable
11. Effective date of appointment: Not applicable
12. Ratio of change in directors during the same term: Not applicable
13. Ratio of change in independent directors during the same term: Not applicable
14. Ratio of change in supervisors during the same term: Not applicable
15. Whether more than one-third of directors have changed: No
16. Other notes: None
FAQ
Does the Polar Vertex Pharma-KY personnel change affect the market?
The change in the subsidiary's director is part of routine group management and is not expected to have a material impact on the market.
What is the role of the newly appointed Hou Yu-hsiang?
He is appointed as a director of Lin-Yang Biotechnology. He currently serves as the HR Director.